The first phase of clinical studies of the national vaccine against Covid-19 RNA MCTI CIMATEC HDT, developed in Bahia, will begin this Thursday (13) in Salvador.
The application of the first dose will take place from 10 am (Brasília time), at the headquarters of the National Industry Service (Senai). The entity is responsible for the vaccine with the North American pharmaceutical company HDT Bio Corp and the Ministry of Science, Technology and Innovation (MCTI), which finances the project.
The National Health Surveillance Agency (Anvisa) authorized the tests in August last year. Participants, who are between 18 and 55 years old, will receive the immunizer in a single dose or in two doses, with different intervals, divided into three groups.
The first group will be vaccinated with two doses 29 days apart. In the second group, two doses will also be given, but with an interval of 57 days. In the third, a single dose will be applied.
The safety, reactogenicity and immunogenicity of the vaccine, which is based on messenger RNA, which synthesizes the virus protein to generate an autoimmune response, will be evaluated at this stage. The technology is also used by Pfizer/BioNtech.
(*With information from Agência Brasil)
Reference: CNN Brasil
